Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis."

Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a Lung Nodule Program: From Detection to Diagnosis." This groundbreaking framework describes six steps to building a comprehensive lung nodule program, with validated biomarker testing, such as the Biodesix Nodify Lung® tests, as a core component of standardizing risk stratification to guide clinical decisions.

The new CHEST framework was developed by a multidisciplinary panel of nationally recognized interventional pulmonologists, thoracic surgeons, and diagnostic radiologists representing leading hospitals and health systems throughout the United States. Drawing on published clinical evidence and real-world experience from established lung nodule programs, the panel defines a practical roadmap for building high performing programs that deliver consistent, evidence-based care and improve outcomes for patients with pulmonary nodules.